纳米医学
免疫系统
免疫疗法
癌症
癌症免疫疗法
医学
免疫学
纳米技术
癌症研究
免疫监视
内科学
材料科学
纳米颗粒
作者
Wen Jiang,Yifan Wang,Jennifer A. Wargo,Frederick F. Lang,Betty Y.S. Kim
标识
DOI:10.1038/s41565-020-00817-9
摘要
Immunotherapy is known to be clinically beneficial for cancer patients and in many cases represents the new standard of care. Because of this success, the interest in integrating nanomedicine with cancer immunotherapy to further improve clinical response and toxicity profiles has grown. However, unlike conventional systemic therapies, which are directly cytotoxic to tumour cells, cancer immunotherapy relies on the host's immune system to generate tumouricidal effects. As such, proper design of cancer immune nanomedicine requires scrutiny of tumours' intrinsic and extrinsic factors that may impact host antitumour immunity. Here, we highlight key parameters that differentiate cancer immunotherapy from conventional cytotoxic agents, and we discuss their implications for designing preclinical cancer immune nanomedicine studies. We emphasize that these factors, including intratumoural genomic heterogeneity, commensal diversity, sexual dimorphism and biological ageing, which were largely ignored in traditional cancer nanomedicine experiments, should be carefully considered and incorporated into cancer immune nanomedicine investigations given their critical involvement in shaping the body's antitumour immune responses.
科研通智能强力驱动
Strongly Powered by AbleSci AI